Lurasidone
Reading File
Finding Sources
Searching PubMed
lurasidone schizophrenia bipolar
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.
Lurasidone (Latuda)
Drug Class & Brand Name
- Class: Second-generation (atypical) antipsychotic - 5-HT2A/D2 antagonist
- Brand name: Latuda
- Available formulations: 20 mg, 40 mg, 80 mg, 120 mg oral tablets
Mechanism of Action
Lurasidone has a multi-receptor pharmacodynamic profile that distinguishes it from many other atypicals:
| Receptor | Action | Clinical Relevance |
|---|---|---|
| D2 (dopamine) | Antagonist (high affinity) | Antipsychotic efficacy; ~60-70% D2 occupancy at 40 mg |
| 5-HT2A (serotonin) | Antagonist (high affinity) | Antipsychotic + antidepressant effect |
| 5-HT7 (serotonin) | Antagonist (high affinity) | Antidepressant properties |
| 5-HT1A (serotonin) | Partial agonist (moderate) | Antidepressant, anxiolytic, reduces EPS |
| α2A, α2C (adrenergic) | Antagonist (moderate) | Potential pro-cognitive effects |
| H1 (histamine) | Negligible affinity | Low sedation, low weight gain |
| M1 (muscarinic) | Negligible affinity | No anticholinergic side effects |
| 5-HT2C | Low affinity | Minimal metabolic impact |
The combination of 5-HT7 antagonism + 5-HT1A partial agonism + 5-HT2A antagonism is thought to underlie its notable antidepressant efficacy in bipolar I depression, as described in Stahl's Essential Psychopharmacology.
FDA-Approved Indications
- Schizophrenia - Adults and adolescents aged 13-17 years
- Major depressive episodes associated with Bipolar I Disorder
- Monotherapy - Adults and pediatric patients (10-17 years)
- Adjunctive therapy with lithium or valproate - Adults
Dosing
| Indication | Starting Dose | Effective Range | Maximum |
|---|---|---|---|
| Schizophrenia | 40 mg once daily | 40-160 mg/day | 160 mg/day |
| Bipolar depression (monotherapy) | 20 mg once daily | 20-120 mg/day | 120 mg/day |
| Bipolar depression (adjunctive) | 20 mg once daily | 20-120 mg/day | 120 mg/day |
Key rule: Must be taken with food (at least 350 calories) - food significantly increases bioavailability. No initial dose titration is required.
Dose adjustments:
- Moderate-to-severe renal impairment: do not exceed 80 mg/day
- Severe hepatic impairment: do not exceed 40 mg/day
- With moderate CYP3A4 inhibitor (e.g., diltiazem): do not exceed 40 mg/day
Pharmacokinetics
| Parameter | Value |
|---|---|
| Oral bioavailability | 9-19% (low; food-dependent) |
| Tmax | 1-3 hours |
| Volume of distribution | 6,173 L (very large) |
| Protein binding | High |
| Metabolism | Primarily CYP3A4 (N-dealkylation, hydroxylation of norbornane ring, S-oxidation) |
| Active metabolites | 2 major active + 2 major inactive |
| Elimination half-life | ~18 hours |
| Route of excretion | Feces (80%), urine (9%) |
NOT a substrate for CYP1A2, CYP2D6, CYP2C9, CYP2C19, or others - simplifying many drug interaction concerns.
Adverse Effects
Common:
- Akathisia (most reported at higher doses)
- Somnolence/sedation (dose at night to minimize)
- Nausea, vomiting, diarrhea
- Extrapyramidal symptoms (parkinsonism)
- Agitation
Favorable metabolic profile (compared to most SGAs):
- Low-to-moderate risk of weight gain
- Minimal effect on glucose and lipids
- This is due to negligible H1 and M1 receptor affinity and low 5-HT2C affinity
Cardiovascular:
- QTc prolongation is modest - 7.5 ms increase at 120 mg; no dose-response relationship observed
- No study participants achieved QTc > 500 ms in clinical trials
- Orthostatic hypotension: ~1.1% of patients
Other serious risks:
- Hyperprolactinemia (class effect)
- Tardive dyskinesia (class effect; highest risk in elderly)
- Neuroleptic malignant syndrome (rare)
- Seizures: 0.1% incidence (premarketing data)
Black Box Warnings
- Increased mortality in elderly patients with dementia-related psychosis (class effect for all SGAs - not approved for this use)
- Suicidal thoughts and behaviors in children, adolescents, and young adults (associated with antidepressant indications)
Contraindications
- Hypersensitivity to lurasidone or any tablet component
- Concurrent use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)
- Concurrent use with strong CYP3A4 inducers (rifampin, St. John's wort, phenytoin, carbamazepine)
Drug Interactions
All mediated through CYP3A4:
- Strong CYP3A4 inhibitors (ketoconazole, ritonavir): CONTRAINDICATED
- Moderate CYP3A4 inhibitors (diltiazem, atazanavir, erythromycin, fluconazole, verapamil): Reduce lurasidone dose by half; max 40 mg/day
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort): CONTRAINDICATED
- Grapefruit / grapefruit juice: Avoid - inhibits CYP3A4
Special Populations
- Pediatric (schizophrenia): Approved age 13+
- Pediatric (bipolar depression): Approved age 10+; one of the preferred agents for this age group due to good tolerability and absence of weight gain
- Elderly / dementia: Carries black box warning; not approved
- Pregnancy / lactation: Use only if benefit outweighs risk
Clinical Pearls
- Bipolar I depression is arguably the primary clinical niche where lurasidone stands out - the 5-HT7/5-HT1A/5-HT2A combination gives robust antidepressant properties. It is often a first-line preferred agent for bipolar depression in the US.
- No titration needed - start at the therapeutic dose
- Night dosing reduces risk of motor side effects and sedation
- It does NOT cause significant anticholinergic side effects, sedation, or weight gain - making it well-tolerated long-term
- A novel combination agent NRX-101 (Cyclurad) - lurasidone + D-cycloserine (a glycine site NMDA receptor antagonist) - is in early clinical development for acute suicidal ideation and bipolar depression
Recent Evidence
A 2026 systematic review and meta-analysis by Ghenciulescu et al. examined the transdiagnostic efficacy of lurasidone on depressive symptoms (PMID: 40831006), published in the British Journal of Psychiatry, supporting broad antidepressant utility across diagnostic categories. A 2026 network meta-analysis by Olgiati et al. (PMID: 41191868) evaluated lurasidone among second- and third-generation antipsychotics for cognitive dysfunction in schizophrenia-spectrum disorders.
Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Kaplan and Sadock's Synopsis of Psychiatry; Stahl's Essential Psychopharmacology (Neuroscientific Basis); The Maudsley Prescribing Guidelines in Psychiatry, 15th ed.
This is a shared conversation. Sign in to Orris to start your own chat.